ABSTRACT

Prostate cancer is a disease most frequently encountered in men over 50 and second only to lung cancer for the number of male deaths in the United States [1] (estimated 33720 deaths in 2011) and United Kingdom [2] (10,382 deaths in 2009). Early detection of the cancer enhances patient recovery, especially if the disease can be detected at the organ-conned stage. A rapid diagnosis of prostate cancer in its early stages could greatly reduce the severity of treatment needed and enhance survival rates. One approach to this could be via the development of methods for detection of prostate-specic antigen (PSA).